A K Burnett

Summary

Affiliation: Cardiff University
Country: UK

Publications

  1. ncbi request reprint Long-term results of the MRC AML10 trial
    Alan K Burnett
    Department of Haematology, University of Wales College of Medicine, Heath Park, Cardiff, CF14 4XN, United Kingdom
    Clin Adv Hematol Oncol 4:445-51. 2006
  2. ncbi request reprint Various distinctive cytogenetic abnormalities in patients with acute myeloid leukaemia aged 60 years and older express adverse prognostic value: results from a prospective clinical trial
    Bronno van der Holt
    Department of Trials and Statistics HOVON Data Centre, Erasmus MC Daniel den Hoed Cancer Centre, Rotterdam, The Netherlands
    Br J Haematol 136:96-105. 2007
  3. pmc The Challenge of AML in Older Patients
    Alan K Burnett
    FMed Sci, Department of Haematology, Cardiff University School of Medicine, Heath Park, Cardiff, United Kingdom
    Mediterr J Hematol Infect Dis 5:e2013038. 2013
  4. doi request reprint Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival
    Alan K Burnett
    Department of Haematology, Cardiff University School of Medicine, Cardiff, United Kingdom
    Blood 122:1384-94. 2013
  5. doi request reprint Curability of patients with acute myeloid leukemia who did not undergo transplantation in first remission
    Alan K Burnett
    Department of Haematology, Cardiff University School of Medicine, Heath Park, Cardiff, UK
    J Clin Oncol 31:1293-301. 2013
  6. doi request reprint Treatment of acute myeloid leukemia: are we making progress?
    Alan K Burnett
    School of Medicine, Cardiff University, Cardiff, United Kingdom
    Hematology Am Soc Hematol Educ Program 2012:1-6. 2012
  7. doi request reprint Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia
    Alan K Burnett
    FMedSci, Department of Haematology, Cardiff University School of Medicine, Heath Park, Cardiff CF14 4XN United Kingdom
    J Clin Oncol 30:3924-31. 2012
  8. doi request reprint The addition of the farnesyl transferase inhibitor, tipifarnib, to low dose cytarabine does not improve outcome for older patients with AML
    Alan K Burnett
    Department of Haematology, Cardiff University School of Medicine, Cardiff, UK
    Br J Haematol 158:519-22. 2012
  9. doi request reprint New induction and postinduction strategies in acute myeloid leukemia
    Alan K Burnett
    Department of Haematology, School of Medicine, Cardiff University, Cardiff, UK
    Curr Opin Hematol 19:76-81. 2012
  10. doi request reprint Therapeutic advances in acute myeloid leukemia
    Alan Burnett
    School of Medicine, Cardiff University, Heath Park, Cardiff CF14 4XN, United Kingdom
    J Clin Oncol 29:487-94. 2011

Detail Information

Publications87

  1. ncbi request reprint Long-term results of the MRC AML10 trial
    Alan K Burnett
    Department of Haematology, University of Wales College of Medicine, Heath Park, Cardiff, CF14 4XN, United Kingdom
    Clin Adv Hematol Oncol 4:445-51. 2006
  2. ncbi request reprint Various distinctive cytogenetic abnormalities in patients with acute myeloid leukaemia aged 60 years and older express adverse prognostic value: results from a prospective clinical trial
    Bronno van der Holt
    Department of Trials and Statistics HOVON Data Centre, Erasmus MC Daniel den Hoed Cancer Centre, Rotterdam, The Netherlands
    Br J Haematol 136:96-105. 2007
    ..Large studies to confirm the prognosis of individual cytogenetic aberrations are warranted...
  3. pmc The Challenge of AML in Older Patients
    Alan K Burnett
    FMed Sci, Department of Haematology, Cardiff University School of Medicine, Heath Park, Cardiff, United Kingdom
    Mediterr J Hematol Infect Dis 5:e2013038. 2013
    ..The outstanding problem for older patients is that remission is usually not durable, and there has been little improvement in overall survival for the last three decades, then new approaches need. ..
  4. doi request reprint Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival
    Alan K Burnett
    Department of Haematology, Cardiff University School of Medicine, Cardiff, United Kingdom
    Blood 122:1384-94. 2013
    ..Although clofarabine doubled remission rates, overall survival was not improved overall or in any subgroup. The treatment of patients of the type treated here remains a major unmet need...
  5. doi request reprint Curability of patients with acute myeloid leukemia who did not undergo transplantation in first remission
    Alan K Burnett
    Department of Haematology, Cardiff University School of Medicine, Heath Park, Cardiff, UK
    J Clin Oncol 31:1293-301. 2013
    ..This evaluation can inform the decision whether to offer a transplant in CR1...
  6. doi request reprint Treatment of acute myeloid leukemia: are we making progress?
    Alan K Burnett
    School of Medicine, Cardiff University, Cardiff, United Kingdom
    Hematology Am Soc Hematol Educ Program 2012:1-6. 2012
    ..Older patients represent a therapeutic challenge, but several new treatments may offer some potential to improve their situation...
  7. doi request reprint Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia
    Alan K Burnett
    FMedSci, Department of Haematology, Cardiff University School of Medicine, Heath Park, Cardiff CF14 4XN United Kingdom
    J Clin Oncol 30:3924-31. 2012
    ..In our previous trial, in younger patients, we showed improved survival for the majority of patients when adding gemtuzumab ozogamicin (GO) to induction chemotherapy...
  8. doi request reprint The addition of the farnesyl transferase inhibitor, tipifarnib, to low dose cytarabine does not improve outcome for older patients with AML
    Alan K Burnett
    Department of Haematology, Cardiff University School of Medicine, Cardiff, UK
    Br J Haematol 158:519-22. 2012
    ..After reviewing the first 45 patients, the Data Monitoring Committee concluded that the overall aspirations would not be met and recommended closure. The addition of tipifarnib had no effect on response, toxicity or survival...
  9. doi request reprint New induction and postinduction strategies in acute myeloid leukemia
    Alan K Burnett
    Department of Haematology, School of Medicine, Cardiff University, Cardiff, UK
    Curr Opin Hematol 19:76-81. 2012
    ..Improving or replacing the traditional induction (3 + 7) and consolidation (high-dose cytarabine; Ara-C) as the standard of care for acute myeloid leukemia (AML) has proved disappointing...
  10. doi request reprint Therapeutic advances in acute myeloid leukemia
    Alan Burnett
    School of Medicine, Cardiff University, Heath Park, Cardiff CF14 4XN, United Kingdom
    J Clin Oncol 29:487-94. 2011
    ..Their survival is approximately 4 months, but there is considerable interest in developing new treatments for this patient group, including novel nucleoside analogs and several other agents...
  11. ncbi request reprint Acute myeloid leukemia: treatment of adults under 60 years
    Alan K Burnett
    Department of Hematology, University of Wales College of Medicine, Heath Park, Cardiff, UK
    Rev Clin Exp Hematol 6:26-45; discussion 86-7. 2002
    ..Modulation of chemoresistance mechanisms or immunologically directed chemotherapy represent immediate prospects for clinical study...
  12. ncbi request reprint Current controversies: which patients with acute myeloid leukaemia should receive a bone marrow transplantation?--an adult treater's view
    Alan K Burnett
    Department of Haematology, University of Wales College of Medicine, Heath Park, Cardiff CF14 4XN, UK
    Br J Haematol 118:357-64. 2002
  13. ncbi request reprint The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial
    Alan K Burnett
    Department of Haematology, University of Wales College of Medicine, Heath Park, Cardiff CF14 4XN, Wales, UK
    Br J Haematol 118:385-400. 2002
    ..This trial found no survival advantage in children, patients over 35 years or good-risk disease...
  14. doi request reprint Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial
    Alan K Burnett
    Department of Haematology, Cardiff University School of Medicine, Heath Park, Cardiff, United Kingdom
    J Clin Oncol 29:369-77. 2011
    ..We previously established that it is feasible to combine GO with conventional chemotherapy. We now report a large randomized trial testing the addition of GO to induction and/or consolidation chemotherapy in untreated younger patients...
  15. ncbi request reprint Evaluating the contribution of allogeneic and autologous transplantation to the management of acute myeloid leukemia in adults
    A K Burnett
    Department of Haematology, University of Wales College of Medicine, Heath Park, Cardiff, UK
    Cancer Chemother Pharmacol 48:S53-8. 2001
    ..Analysis within risk groups suggests that transplantation for good-risk patients is not appropriate and the role of transplantation is uncertain in other groups...
  16. doi request reprint Attempts to optimize induction and consolidation treatment in acute myeloid leukemia: results of the MRC AML12 trial
    Alan K Burnett
    Department of Haematology, School of Medicine, Cardiff University, Cardiff, United Kingdom
    J Clin Oncol 28:586-95. 2010
    ..To optimize treatment for younger patients with acute myeloid leukemia and high-risk myelodysplastic syndrome by comparing induction options and the number of consolidation courses and whether consolidation should include transplantation...
  17. doi request reprint The impact on outcome of the addition of all-trans retinoic acid to intensive chemotherapy in younger patients with nonacute promyelocytic acute myeloid leukemia: overall results and results in genotypic subgroups defined by mutations in NPM1, FLT3, and C
    Alan K Burnett
    Department of Haematology, Cardiff University School of Medicine, Cardiff, UK
    Blood 115:948-56. 2010
    ..ATRA has no overall effect on treatment outcomes in this group of patients. The study did not identify any subgroup of patients likely to derive a significant survival benefit from the addition of ATRA to chemotherapy...
  18. doi request reprint The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome: the results of the LRF AML14 trial
    Alan K Burnett
    Department of Haematology, School of Medicine, Cardiff University Heath Park, Cardiff, UK
    Br J Haematol 145:318-32. 2009
    ..In conclusion, these four interventions have not improved outcomes in older patients. New agents need to be explored and novel trial designs are required to maximise prospects of achieving timely progress...
  19. doi request reprint Tipifarnib in acute myeloid leukemia
    Alan K Burnett
    Department of Haematology, School of Medicine, Cardiff University, Cardiff, UK
    Drugs Today (Barc) 43:795-800. 2007
    ..Several randomized comparative and combination trials have been set up that will establish the position of tipifarnib in the treatment of AML...
  20. doi request reprint The addition of arsenic trioxide to low-dose Ara-C in older patients with AML does not improve outcome
    A K Burnett
    Department of Haematology, Cardiff University School of Medicine, Heath Park, Cardiff, UK
    Leukemia 25:1122-7. 2011
    ..Grade 3/4 cardiac and liver toxicity, and supportive care requirements were greater in the ATO arm. This randomised comparison demonstrates that adding ATO to LDAC provides no benefit for older patients with AML...
  21. doi request reprint Who should be transplanted in first remission of acute myeloid leukaemia?
    Alan K Burnett
    Department of Haematology, School of Medicine, Cardiff University, Heath Park, UK
    Curr Treat Options Oncol 12:329-40. 2011
    ..g. >2 years. The possible exception to this could be core binding factor leukaemias who may have durable survival after relapse with transplant alone...
  22. ncbi request reprint Treatment of older patients with acute myeloid leukemia--new agents
    Alan K Burnett
    Department of Haematology, University Hospital of Wales, Cardiff, UK
    Semin Hematol 43:96-106. 2006
    ..With several new agents to evaluate, novel approaches to trial design aimed at detecting options likely to make a useful impact are needed...
  23. doi request reprint European development of clofarabine as treatment for older patients with acute myeloid leukemia considered unsuitable for intensive chemotherapy
    Alan K Burnett
    Department of Haematology, Cardiff University School of Medicine, Cardiff CF14 4XN, United Kingdom
    J Clin Oncol 28:2389-95. 2010
    ..We assessed the second-generation purine nucleoside analog, clofarabine, in two similar phase II studies in this group of patients...
  24. ncbi request reprint Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: result of the Randomized MRC Trial
    A K Burnett
    Department of Haematology, University of Wales College of Medicine, Cardiff, UK
    Blood 93:4131-43. 1999
    ..Molecular characterization of disease can improve diagnostic precision and a positive RT-PCR after consolidation identifies patients at a higher risk of relapse...
  25. ncbi request reprint High dose cytarabine or transplantation for consolidation of younger patients with acute myeloid leukemia
    A K Burnett
    University of Wales College of Medicine, Cardiff, United Kingdom
    Curr Opin Oncol 12:110-5. 2000
    ..The trials that included high-dose cytarabine (ara-C) in the chemotherapy schedule were the ones in which no survival benefit was seen...
  26. ncbi request reprint Acute myeloid leukemia: therapeutic indications
    A K Burnett
    Department of Haematology, University of Wales College of Medicine, Cardiff, UK
    Curr Opin Hematol 7:333-8. 2000
    ..Improved understanding of resistance mechanisms and the identification of new risk factors may enable the development of a more targeted approach to therapy...
  27. ncbi request reprint The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial
    D Grimwade
    Department of Haematology, University College London Hospitals and Medical School, London, United Kingdom
    Blood 98:1312-20. 2001
    ..Furthermore, it highlights the importance of karyotype as a critical independent determinant of outcome in older patients with AML, providing a potential framework for stratified treatment approaches...
  28. ncbi request reprint Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial
    A H Goldstone
    Department of Haematology, University College Hospital, London, United Kingdom
    Blood 98:1302-11. 2001
    ....
  29. ncbi request reprint Inhibition of mitochondrial function in HL60 cells is associated with an increased apoptosis and expression of CD14
    K I Mills
    Department of Haematology, University of Wales College of Medicine, Cardiff, Heath Park, United Kingdom
    Biochem Biophys Res Commun 263:294-300. 1999
    ..These results suggest that inhibition of the components of the mitochondrial pathways may lead to the marking of some cells, via CD14, for cell death, whilst allowing commitment to differentiation to occur in the surviving population...
  30. doi request reprint The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: results from the LRF AML14 and NCRI AML16 pick-a-winner comparison
    A K Burnett
    Department of Haematology, Cardiff University School of Medicine, Cardiff, UK
    Leukemia 27:75-81. 2013
    ..Although the addition of GO to LDAC doubled the remission rate it did not improve overall survival. Maintaining remission in older patients remains elusive...
  31. ncbi request reprint EVI1 expression in acute myeloid leukaemia
    S E Langabeer
    Department of Haematology, University College London Hospitals and Medical School, London, UK
    Br J Haematol 112:208-11. 2001
    ..This study nevertheless demonstrates that deregulation of EVI1, although rare in APL, is a relatively frequent event in AML...
  32. ncbi request reprint Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations
    Claire L Green
    Department of Haematology, UCL Cancer Institute, University College London, 72 Huntley St, London, UK
    J Clin Oncol 28:2739-47. 2010
    ..To determine the clinical relevance of mutations in the CCAAT/enhancer binding protein alpha (CEBPA) gene in acute myeloid leukemia (AML) and to examine factors that might modify prognostic impact...
  33. doi request reprint Inclusion of chemotherapy in addition to anthracycline in the treatment of acute promyelocytic leukaemia does not improve outcomes: results of the MRC AML15 trial
    A K Burnett
    Department of Haematology, School of Medicine, Cardiff University, Cardiff, UK
    Leukemia 27:843-51. 2013
    ..Both approaches deliver similar results with minor differences in quality of life. MRC treatment required more hospitalisation. This suggests that additional chemotherapy, Ara-C in particular, is not required...
  34. ncbi request reprint An in vivo and in vitro comparison of the effects of b2-a2 and b3-a2 p210BCR-ABL splice variants on murine 32D cells
    B A Guinn
    Department of Haematology, University of Wales College of Medicine, Cardiff, United Kingdom
    Leuk Lymphoma 37:393-404. 2000
    ..This panel of BCR-ABL expressing 32D cells provides a useful model for CML disease progression studies...
  35. ncbi request reprint A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia
    William J Kell
    Department of Haematology, University of Wales College of Medicine, Heath Park, Cardiff, CF14 4XN, Wales
    Blood 102:4277-83. 2003
    ..GO given with induction (DA or FLAG-Ida) and consolidation (MACE or HidAC) was well tolerated. These schedules are now being compared in the MRC AML15 trial in patients younger than 60 years...
  36. doi request reprint The importance of relative mutant level for evaluating impact on outcome of KIT, FLT3 and CBL mutations in core-binding factor acute myeloid leukemia
    C Allen
    Department of Haematology, UCL Cancer Institute, London, UK
    Leukemia 27:1891-901. 2013
    ..These results indicate that relative mutant level should be taken into account when evaluating the impact of mutations in CBF-AML. ..
  37. ncbi request reprint The MEK inhibitor, PD98059, reduces survival but does not block acute myeloid leukemia blast maturation in vitro
    P Baines
    Haematology Department, University Hospital of Wales and University of Wales College of Medicine, Cardiff, UK
    Eur J Haematol 64:211-8. 2000
    ..The MAPKinase pathway is not required for this maturation, but it does maintain cell viability in the absence or presence of cytokines. A rise in Bcl-2 may not protect AML blasts in the face of elevated Bax...
  38. ncbi request reprint Unravelling an HLA-DR association in childhood acute lymphoblastic leukemia
    M T Dorak
    Department of Haematology, University of Wales College of Medicine, Cardiff, Wales, UK
    Blood 94:694-700. 1999
    ....
  39. ncbi request reprint Role of allogeneic and autologous hematopoietic stem cell transplantation in acute myeloid leukemia
    A K Burnett
    Department of Hematology, University of Wales College of Medicine, Cardiff Wales, United Kingdom
    Int J Hematol 72:280-4. 2000
    ..Poor-risk patients have a higher failure rate after transplantation, and for these patients novel approaches are required...
  40. pmc γ-Catenin is overexpressed in acute myeloid leukemia and promotes the stabilization and nuclear localization of β-catenin
    R G Morgan
    Department of Hematology, Institute of Cancer and Genetics, School of Medicine, Cardiff University, Wales, Cardiff, UK
    Leukemia 27:336-43. 2013
    ....
  41. ncbi request reprint Transcriptional dysregulation mediated by RUNX1-RUNX1T1 in normal human progenitor cells and in acute myeloid leukaemia
    A Tonks
    Department of Haematology, School of Medicine, Cardiff University, Cardiff, UK
    Leukemia 21:2495-505. 2007
    ..These data provide the most comprehensive and pertinent assessment of the effect of RUNX1-RUNX1T1 on gene expression and demonstrate the highly context-dependent effects of this fusion gene...
  42. pmc CD200 expression suppresses natural killer cell function and directly inhibits patient anti-tumor response in acute myeloid leukemia
    S J Coles
    Department of Medical Genetics, Haematology and Pathology, Cardiff University, Cardiff, UK
    Leukemia 25:792-9. 2011
    ..Together, these findings provide the first evidence that CD200 has a direct and significant suppressive influence on NK cell activity in AML patients and may contribute to the increased relapse rate in CD200(+) patients...
  43. ncbi request reprint The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United King
    P D Kottaridis
    Department of Haematology, University College London, London, United Kingdom
    Blood 98:1752-9. 2001
    ..The suggestion is made that detection of a FLT3/ITD should be included as a routine test at diagnosis and evaluated for therapeutic management...
  44. ncbi request reprint Treatment of acute myeloid leukaemia in younger patients
    A K Burnett
    Department of Haematology, University of Wales College of Medicine, Heath Park, Cardiff, CF14 4XN, UK
    Best Pract Res Clin Haematol 14:95-118. 2001
    ..It is possible that technical improvements in transplantation, such as peripheral blood as a source of stem cells, may remove this uncertainty...
  45. ncbi request reprint A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment
    Alan K Burnett
    Department of Haematology, Wales School of Medicine, Cardiff University, Cardiff, United Kingdom
    Cancer 109:1114-24. 2007
    ..The survival of older patients with acute myeloid leukemia has not improved. Few clinical trials have been available for older patients who are not considered fit for an intensive chemotherapy approach...
  46. ncbi request reprint The treatment of AML: current status and novel approaches
    Alan K Burnett
    Wales School of Medicine, Cardiff University, Heath Park, Cardiff, CF14 4XN
    Hematology 10:50-3. 2005
  47. ncbi request reprint Increased heterozygosity for MHC class II lineages in newborn males
    M T Dorak
    Department of Haematology, University of Wales College of Medicine, Cardiff CF14 4XN, UK
    Genes Immun 3:263-9. 2002
    ..These results provide an appealing working hypothesis for further studies in humans and other vertebrates...
  48. ncbi request reprint Abnormalities of adherent layers grown from bone marrow of patients with myelodysplasia
    G B Tennant
    Department of Haematology, University of Wales College of Medicine, Cardiff, UK
    Br J Haematol 111:853-62. 2000
    ..Thus, the adherent layers in cultures grown from MDS patients were haemopoietically defective and showed abnormal IL-1 beta expression...
  49. ncbi request reprint Mutant RAS inhibits neutrophil but not macrophage differentiation and allows continued growth of neutrophil precursors
    R L Darley
    Department of Haematology, University of Wales College of Medicine, Cardiff, United Kingdom
    Exp Hematol 27:1599-608. 1999
    ..These findings suggest that activation of RAS is able to specifically inhibit terminal neutrophil differentiation and in so doing promotes continued division of metamyelocyte cells...
  50. pmc Restriction endonuclease isoschizomers ItaI, BsoFI and Fsp4HI are characterised by differences in their sensitivities to CpG methylation
    B H Ramsahoye
    Department of Haematology, University of Wales College of Medicine, Heath Park, Cardiff CF4 4XN, UK
    Nucleic Acids Res 25:3196-8. 1997
    ..Considerable variation in the rate of cleavage by BsoFI is also observed at sites containing only internal methylated CpG. Some sites are cut slowly, whilst others fail to cut even after prolonged incubation with excess of enzyme...
  51. ncbi request reprint FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia
    Adam J Mead
    Department of Haematology, Royal Free and University College Medical School, London, United Kingdom
    Blood 110:1262-70. 2007
    ....
  52. ncbi request reprint Prognosis of myelodysplasic patients: non-parametric multiple regression analysis of populations stratified by mean corpuscular volume and marrow myeloblast number
    Graham B Tennant
    Department of Haematology, University of Wales College of Medicine, Cardiff, UK
    Br J Haematol 119:87-96. 2002
    ..Further analysis defined factors identifying very high-risk patients and those with benign disease, together with many intermediate survival patterns. Results were consistent in two time-separated patient groups...
  53. doi request reprint The cyclin-dependent kinase inhibitor SNS-032 has single agent activity in AML cells and is highly synergistic with cytarabine
    E Walsby
    Cardiff Experimental Cancer Medicine Centre, Department of Haematology, School of Medicine, Cardiff University, Heath Park, Cardiff, UK
    Leukemia 25:411-9. 2011
    ..Therefore, the combination of SNS-032 and Ara-C may increase the sensitivity of AML cells to the cytotoxic effects of Ara-C by inhibiting the transcription of antiapoptotic genes...
  54. ncbi request reprint Control of pH in human long-term bone marrow cultures with low-glucose medium containing zwitterion buffer lengthens the period of haemopoietic activity
    G B Tennant
    Department of Haematology, University of Wales College of Medicine, Heath Park, Cardiff, UK
    Br J Haematol 109:785-7. 2000
    ..Improved control of medium pH significantly improved the capacity of long-term stromal layers to maintain stem cells in vitro...
  55. ncbi request reprint Expression of AML1-ETO in human myelomonocytic cells selectively inhibits granulocytic differentiation and promotes their self-renewal
    A Tonks
    Department of Haematology, University of Wales College of Medicine, Cardiff, UK
    Leukemia 18:1238-45. 2004
    ..Taken together, these results suggest that expression of AML1-ETO selectively inhibits the differentiation of granulocytic cells and promoted extensive self-renewal, supporting a causal role for t(8;21) translocations in leukaemogenesis...
  56. ncbi request reprint The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia
    Rosemary E Gale
    Department of Haematology, Royal Free and University College Medical School, University College London, 98 Chenies Mews, London, UK
    Blood 111:2776-84. 2008
    ..Patients with high FLT3/ITD mutant level (greater than 50%) or FLT3/ITD(+) in the absence of an NPM1 mutation may be good candidates for more experimental therapeutic approaches...
  57. ncbi request reprint Chemotherapy-induced cardiotoxicity: current practice and prospects of prophylaxis
    M I Gharib
    Department of Haematology, University of Wales College of Medicine, Heath Park, Cardiff, CF14 4XW, UK
    Eur J Heart Fail 4:235-42. 2002
    ..Work is currently progressing to identify the role of markers such as troponins and natriuretic peptides in this regard...
  58. doi request reprint OGG1 is a novel prognostic indicator in acute myeloid leukaemia
    K Liddiard
    Department of Haematology, School of Medicine, Cardiff University, Cardiff, UK
    Oncogene 29:2005-12. 2010
    ....
  59. ncbi request reprint Increasing methylation of the calcitonin gene during disease progression in sequential samples from CML patients
    K I Mills
    Department of Haematology, University of Wales College of Medicine, Cardiff, U K
    Leuk Res 20:771-5. 1996
    ....
  60. ncbi request reprint A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy
    Steven Knapper
    Department of Haematology, Cardiff University School of Medicine, Heath Park, Cardiff, CF14 4XW, United Kingdom
    Blood 108:3262-70. 2006
    ..Further evaluation of this compound, in combination with cytotoxic chemotherapy or other targeted agents, is warranted in both FLT3 mutant and wild-type patients...
  61. ncbi request reprint Relationship between FLT3 mutation status, biologic characteristics, and response to targeted therapy in acute promyelocytic leukemia
    Rosemary E Gale
    Department of Haematology, University College London Hospitals, United Kingdom
    Blood 106:3768-76. 2005
    ..Furthermore, in the presence of CEP-701, ATRA-induced differentiation was reduced in FLT3/ITD+ cells. These data carry implications for the use of FLT3 inhibitors as frontline therapy for APL...
  62. ncbi request reprint The role of PKC and PDK1 in monocyte lineage specification by Ras
    Lorna Pearn
    Department of Haematology, School of Medicine, Cardiff University, Cardiff, United Kingdom
    Blood 109:4461-9. 2007
    ..These data demonstrate that Ras is able to promote monocyte lineage selection via PKC and show for the first time the involvement of the kinase master regulator, PDK1, in both lineage specification and in human leukemia...
  63. ncbi request reprint No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML): an analysis of 1135 patients, excluding acute promyelocytic leukemia, from the UK MRC AML10 and 12 trials
    Rosemary E Gale
    Department of Haematology, Royal Free and University College Medical School, London, UK
    Blood 106:3658-65. 2005
    ..70, CIs = 0.53-0.92; FLT3/ITD(+) OR = 0.59, CIs = 0.40-0.87; test for interaction, P = .5). These results suggest that at present there is no strong evidence that FLT3 status should influence the decision to proceed to transplantation...
  64. ncbi request reprint A European network for AML
    Alan K Burnett
    University of Wales College of Medicine, Cardiff, UK
    Hematol J 5:S44-5. 2004
  65. ncbi request reprint A C-terminal FMS mutation in a patient with B-cell malignancy
    A H Baker
    Department of Haematology, University of Wales College of Medicine, Cardiff, UK
    Leukemia 9:155-8. 1995
    ..However, the presence of other mutations not detected using this type of analysis cannot be excluded...
  66. ncbi request reprint Invasive aspergillosis localised to the colon presenting as toxic megacolon
    U Mohite
    Department of Haematology, University of Wales, Cardiff, UK
    Eur J Haematol 78:270-3. 2007
    ..The increased awareness, high degree of clinical suspicion of unusual presentation and early surgical intervention with aggressive antifungal treatment, has a key role in the management of these rare and often fatal cases...
  67. ncbi request reprint Identification of a retinoic acid responsive aldoketoreductase expressed in HL60 leukaemic cells
    K I Mills
    Department of Haematology, University of Wales College of Medicine, Cardiff, UK
    FEBS Lett 440:158-62. 1998
    ....
  68. ncbi request reprint The effects of lestaurtinib (CEP701) and PKC412 on primary AML blasts: the induction of cytotoxicity varies with dependence on FLT3 signaling in both FLT3-mutated and wild-type cases
    Steven Knapper
    Department of Haematology, Cardiff University School of Medicine, Heath Park, Cardiff, CF14 4XW, United Kingdom
    Blood 108:3494-503. 2006
    ....
  69. pmc Ral is both necessary and sufficient for the inhibition of myeloid differentiation mediated by Ras
    Nader Omidvar
    Department of Haematology, School of Medicine, Cardiff School of Biosciences, Cardiff University, Museum Avenue, Cardiff, United Kingdom
    Mol Cell Biol 26:3966-75. 2006
    ..Ral, in turn, appears to influence differentiation through multiple effectors. These data show, for the first time, the importance of Ral in regulating differentiation and self-renewal in hematopoietic cells...
  70. ncbi request reprint The NF-kappaB inhibitor LC-1 has single agent activity in multiple myeloma cells and synergizes with bortezomib
    Elisabeth J Walsby
    Department of Haematology, School of Medicine, Cardiff University, Cardiff, United Kingdom
    Mol Cancer Ther 9:1574-82. 2010
    ..Furthermore, LC-1-induced transcriptional suppression of survivin and MCL1 provides a potential explanation for its synergy with conventional agents...
  71. doi request reprint The prognostic significance of IDH1 mutations in younger adult patients with acute myeloid leukemia is dependent on FLT3/ITD status
    Claire L Green
    Department of Haematology, UCL Cancer Institute, London, UK
    Blood 116:2779-82. 2010
    ..008) and a favorable factor in FLT3/ITD(+) patients (P = .02). These results suggest that metabolic changes induced by an IDH1 mutation may influence chemoresistance in a manner that is context-dependent...
  72. ncbi request reprint The novel nuclear factor-kappaB inhibitor LC-1 is equipotent in poor prognostic subsets of chronic lymphocytic leukemia and shows strong synergy with fludarabine
    Saman Hewamana
    Department of Haematology, School of Medicine, Cardiff University, Cardiff, United Kingdom
    Clin Cancer Res 14:8102-11. 2008
    ..Here we elucidated the mechanism of action of LC-1, evaluated its relative cytotoxicity in prognostic subsets, and investigated its potential synergistic interaction with fludarabine...
  73. ncbi request reprint Photosensitivity and acute liver injury in myeloproliferative disorder secondary to late-onset protoporphyria caused by deletion of a ferrochelatase gene in hematopoietic cells
    Richard G Goodwin
    Department of Dermatology, University Hospital of Wales, Cardiff, United Kingdom
    Blood 107:60-2. 2006
    ....
  74. pmc Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis: results from the international ALL trial MRC UKALL XII/ECOG E2993
    Hillard M Lazarus
    Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH 44106, USA
    Blood 108:465-72. 2006
    ..03) for those without. CNS leukemia in adult ALL is uncommon at diagnosis. Adult Ph-negative ALL patients, however, can attain long-term disease-free survival using SCT as well as conventional chemotherapy...
  75. pmc CD34-related coexpression of MDR1 and BCRP indicates a clinically resistant phenotype in patients with acute myeloid leukemia (AML) of older age
    Marry M van den Heuvel-Eibrink
    Department of Hematology, P O Erasmus MC, Dr Molewaterplein 40, 3015 GJ, Rotterdam, The Netherlands
    Ann Hematol 86:329-37. 2007
    ..When adjusted for other prognostic actors, only CD34-related MDR1/BCRP coexpression remained significantly associated with a lower CR rate (p = 0.03), thereby identifying a clinically resistant subgroup of elderly AML patients...
  76. ncbi request reprint Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993
    Jacob M Rowe
    Department of Hematology and Bone Marrow Transplantation, Rambam Medical Center and Technion, Israel Institute of Technology, Haifa 31096, Israel
    Blood 106:3760-7. 2005
    ..However, the achievement of CR within 4 weeks does not appear to be an independent prognostic factor...
  77. ncbi request reprint Fludarabine and cytosine are less effective than standard ADE chemotherapy in high-risk acute myeloid leukemia, and addition of G-CSF and ATRA are not beneficial: results of the MRC AML-HR randomized trial
    Donald W Milligan
    Department of Haemotology, Birmingham Heartlands Hospital, Birmingham B9 5SS, UK
    Blood 107:4614-22. 2006
    ..In conclusion these findings indicate that FLA may be inferior to standard chemotherapy in high-risk AML and that the outcome is not improved with the addition of either G-CSF or ATRA...
  78. ncbi request reprint In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/
    Anthony H Goldstone
    North London Cancer Network, University College London Hospitals, London, United Kingdom
    Blood 111:1827-33. 2008
    ..There is no evidence that a single autologous transplantation can replace consolidation/maintenance in any risk group. This study is registered at http://clinicaltrials.gov as NCT00002514...
  79. ncbi request reprint RAS mutation in acute myeloid leukemia is associated with distinct cytogenetic subgroups but does not influence outcome in patients younger than 60 years
    David T Bowen
    Division of Pathology and Neuroscience, Ninewells Hospital, Dundee DD1 9SY, United Kingdom
    Blood 106:2113-9. 2005
    ..RAS mutation did not influence clinical outcome (overall/disease-free survival, complete remission, relapse rate) either for the entire cohort or within cytogenetic risk groups...
  80. ncbi request reprint The emerging role of targeted therapy for hematologic malignancies: update on bortezomib and tipifarnib
    Jean Pierre Armand
    Institut Gustave Roussy, Dept of Medicine, 39 rue Camille Desmoulins, Villejuif Cedex 94805, France
    Oncologist 12:281-90. 2007
    ..Continued investigation with these new, targeted treatments will further define their use as treatment options in patients with hematologic cancer...
  81. ncbi request reprint Fludarabine, cytosine arabinoside, granulocyte-colony stimulating factor with or without idarubicin in the treatment of high risk acute leukaemia or myelodysplastic syndromes
    Donald W Milligan
    Br J Haematol 127:238-9. 2004
  82. ncbi request reprint Progress in the treatment of acute myeloid leukemia
    Farhad Ravandi
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 110:1900-10. 2007
    ....
  83. ncbi request reprint Long-term survival of myelodysplastic patients with macrocytosis
    Graham B Tennant
    Br J Haematol 124:840-1. 2004
  84. ncbi request reprint Problems with up-front randomization in clinical trials
    Keith Wheatley
    J Clin Oncol 24:5471-2; author reply 5472-3. 2006
  85. ncbi request reprint The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis
    Bronno van der Holt
    Department of Hematology, Erasmus MC, PO Box 2040, 3000 CA Rotterdam, The Netherlands
    Blood 106:2646-54. 2005
    ..The role of strategies aimed at inhibitory P-gp and other drug-resistance mechanisms continues to be defined in the treatment of patients with AML...
  86. ncbi request reprint The tumour antigens RAGE-1 and MGEA6 are expressed more frequently in the less lineage restricted subgroups of presentation acute myeloid leukaemia
    Barbara Ann Guinn
    Br J Haematol 134:238-9. 2006
  87. ncbi request reprint Microarray analysis of tumour antigen expression in presentation acute myeloid leukaemia
    Barbara Ann Guinn
    Department of Haematological Medicine, Guy s, King s and St Thomas School of Medicine, King s College London, London SE5 9NU, UK
    Biochem Biophys Res Commun 333:703-13. 2005
    ..We have identified a number of CT antigens with expression in presentation AML samples but not normal donor samples, which may provide effective targets for future immunotherapy treatments early in disease...